News | September 03, 2014

Research at Jobst Vascular Institute Examines Safety and Effectiveness of Stents for Veins


September 3, 2014 — Jobst Vascular Institute is conducting pioneering research that looks at using stents to treat blocked veins. For years, stents have been used to treat narrowed or blocked arteries; however none are specifically designed for use in veins. The Cook Medical VIVO clinical research study aims to determine the safety and effectiveness of the Zilver vena venous self-expanding stent in the treatment of vein obstructions. Jobst Vascular Institute is the second center in the country to enroll a patient in the VIVO clinical research study.

“Veins differ greatly from arteries and require a different approach when treating blockages,” said Anthony Comerota, M.D., one of two global principal investigators in the VIVO clinical research study. “While arteries are muscular and under high pressure as they deliver blood throughout the body, veins are low-pressure vessels that return blood to the heart. When obstructed, they require stent characteristics different from those required by an artery.”

Vein obstruction or iliofemoral venous outflow obstruction is a blockage or narrowing of the major veins draining blood from the leg. It causes leg pain, throbbing, swelling and skin discoloration in the legs. It may also be associated with deep vein thrombosis, a blood clot in the leg. Patients are currently treated only with compression stockings or by elevating the leg. Some patients may be taking blood thinners.

“This is an important trial, which may expand the options for treating diseased veins,” said Comerota.

The Zilver vena venous self-expanding stent is an investigational device that is not approved for sale in the United States.

For more information: www.promedica.org/jobst, www.cookmedical.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now